Remove 2012 Remove Individual Remove Medical Remove Supply Chain
article thumbnail

Why, Who, When, Where and More: New Draft Guidance on Notifying FDA about Discontinuance or Interruption in Manufacturing

FDA Law Blog

By Véronique Li, Senior Medical Device Regulation Expert & Deborah L. Early notification can play a role in decreasing the impact and duration of such supply disruptions and product shortages. API and its source and any alternative sources; associated medical devices), and expected duration of the interruption.

article thumbnail

Does the Drug Shortage White Paper Fall Short?

FDA Law Blog

Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response. In Section I.A,